Jerome Powell speaking at Jackson Hole, signals a September rate cut
MENLO PARK, CA—Jeremy B. Hayden, the Chief Legal Officer of Sight Sciences , Inc. (NASDAQ:SGHT), recently sold shares of the company’s common stock, according to a recent SEC filing. On April 2, Hayden sold 9,395 shares at an average price of $2.309 per share, totaling approximately $21,693. The transaction comes amid a challenging period for the company’s stock, which has declined over 61% in the past six months and currently trades near its 52-week low of $2.04. The transaction was made to cover the tax liability associated with the vesting of restricted stock units. Following this sale, Hayden retains direct ownership of 275,481 shares in the company. Sight Sciences, based in Menlo Park, specializes in surgical and medical instruments. The company maintains a strong liquidity position with a current ratio of 9.04 and more cash than debt on its balance sheet. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment, with 8 additional exclusive insights available to subscribers.
In other recent news, Sight Sciences reported its fourth-quarter 2024 earnings, which fell short of expectations. The company recorded revenue of $19.1 million, missing the forecast of $20.26 million, and an earnings per share (EPS) of -$0.23, slightly below the anticipated -$0.22. The revenue increase of 2% year-over-year was driven by a 9% growth in surgical glaucoma revenue, although the dry eye segment saw a significant decline. Stifel analysts have adjusted their price target for Sight Sciences to $4.00 from $5.00, while maintaining a Buy rating, citing challenges in the Surgical Glaucoma segment due to changes in Medicare Local Coverage Determinations. Despite these challenges, analysts at Stifel remain optimistic about potential reimbursement for the company’s TearCare product, which could be a catalyst for future revenue growth. Sight Sciences has provided a revenue guidance range of $70 million to $75 million for 2025, reflecting continued headwinds in the Surgical Glaucoma segment. The company remains focused on achieving reimbursement for TearCare and expanding its presence in the minimally invasive glaucoma surgery market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.